Mirtazapin Actavis (Mirtazapine)

Mirtazapine blocks presynaptic α2‑adrenergic receptors, leading to increased release of norepinephrine, and antagonises 5‑HT2, 5‑HT3 and H1 receptors. This dual action enhances noradrenergic and serotonergic neurotransmission while reducing histamine‑mediated sedation, producing an overall antidepressant effect.

The appropriate dose of Mirtazapin Actavis is determined by the prescribing clinician based on the individual’s clinical condition, response to therapy and tolerability. Dosage adjustments are made during treatment, and patients should follow the prescriber’s instructions without self‑adjusting the amount.

Safety data for mirtazapine in pregnancy and lactation are limited. The prescriber must weigh potential benefits against possible risks to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss the use of Mirtazapin Actavis with their healthcare provider.

To request Mirtazapin Actavis, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mirtazapin Actavis belongs to the NaSSA class, which differs from selective serotonin reuptake inhibitors (SSRIs) and serotonin‑norepinephrine reuptake inhibitors (SNRIs) by its receptor‑blocking profile. It often provides stronger sedative and appetite‑stimulating effects, making it useful when insomnia or weight loss are prominent concerns.

Mirtazapin Actavis should be stored at ambient temperature, below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

Mirtazapin Actavis is taken orally, usually once daily in the evening to take advantage of its sedative properties. The tablet should be swallowed whole with water and not chewed or crushed unless otherwise directed by a healthcare professional.

Serious risks include the potential for agranulocytosis or severe neutropenia, hypersensitivity reactions such as Stevens‑Johnson syndrome, emergence or worsening of suicidal thoughts, and rare cases of serotonin syndrome when combined with other serotonergic drugs. Prompt medical attention is required if any of these occur.

Mirtazapin Actavis is contraindicated in patients who have a known hypersensitivity to mirtazapine or any of its excipients, and in those currently receiving monoamine oxidase inhibitors (MAOIs) without an appropriate washout period. Caution is also advised for individuals with severe hepatic impairment or a history of blood dyscrasias.